T1	Participants 136 161	treatment of recurrent or
T2	Participants 162 200	refractory non small-cell lung cancer.
T3	Participants 932 1054	All patients had histologically confirmed nonsquamous NSCLC that had progressed during or after one platinum-based regimen
T4	Participants 1064 1091	One hundred twenty patients
T5	Participants 1606 1713	bevacizumab-chemotherapy and 0.72 (95% CI, 0.42 to 1.23) among patients treated with bevacizumab-erlotinib.
T6	Participants 1578 1605	among patients treated with
